Novocure to present Phase 3 PANOVA-3 trial results at ASCO 2025

Novocure (NVCR) announced that it will present additional results from the Phase 3 PANOVA-3 trial of its Tumor Treating Fields therapy for pancreatic cancer at the 2025 American Society of Clinical Oncology Annual Meeting, taking place May 30 to June 3 in Chicago. The PANOVA-3 trial evaluated the use of TTFields therapy concomitantly with gemcitabine and nab-paclitaxel as a first-line treatment for unresectable, locally advanced pancreatic adenocarcinoma. The company previously announced positive topline results from PANOVA-3 that demonstrated the trial met its primary endpoint, achieving a statistically significant improvement in median overall survival in patients treated with TTFields therapy concomitantly with gemcitabine and nab-paclitaxel compared to those treated with gemcitabine and nab-paclitaxel alone.